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Abstract
RNA modalities are developing as a powerful means to re-direct pathogenic pre-mRNA splicing events. Improving the
efficiency of these molecules in vivo is critical as they move towards clinical applications. Spinal muscular atrophy (SMA) is
caused by loss of SMN1. A nearly identical copy gene called SMN2 produces low levels of functional protein due to
alternative splicing. We previously reported a trans-splicing RNA (tsRNA) that re-directed SMN2 splicing. Now we show that
reducing the competition between endogenous splices sites enhanced the efficiency of trans-splicing. A single vector
system was developed that expressed the SMN tsRNA and a splice-site blocking antisense (ASO-tsRNA). The ASO-tsRNA
vector significantly elevated SMN levels in primary SMA patient fibroblasts, within the central nervous system of SMA mice
and increased SMN-dependent in vitro snRNP assembly. These results demonstrate that the ASO-tsRNA strategy provides
insight into the trans-splicing mechanism and a means of significantly enhancing trans-splicing activity in vivo.
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Introduction
Trans-splicing has recently been envisioned as a potential
therapeutic intervention for a variety of genetic diseases. The
potential effectiveness of this strategy has been demonstrated in a
variety of diseases including spinal muscular atrophy, cystic
fibrosis, hyper-IgM X-linked immunodeficiency, hemophilia A,
Alzheimer’s disease, and epidermolysis bullosa simplex with
muscular dystrophy [1–6]. Trans-splicing is a natural, albeit
infrequently utilized process in mammals, therefore, maximizing
efficiency is central to developing trans-splicing therapeutics [7].
Conceptually, this strategy relies upon nuclear pre-mRNA splicing
occurring between two different molecules: 1) the mutant
endogenous RNA and 2) the exogenous therapeutic RNA that
provides the correct RNA sequence via a trans-splicing event.
Spinal Muscular Atrophy (SMA), a neurodegenerative disorder,
is caused by the homozygous loss of survival motor neuron 1 (SMN1)
and is the leading genetic cause of infantile death [8,9]. In humans
two copies of the SMN gene exist, SMN1 and SMN2 [10]. The
critical distinction between the two genes occurs at the RNA
processing level: SMN1 produces full-length transcripts, while
SMN2 primarily produces an alternatively spliced transcript
lacking the final coding exon [10]. A single silent C to T non-
polymorphic nucleotide difference is responsible for disrupting a
critical splice enhancer element in SMN2 exon 7 [11,12].
SMN2 is retained in essentially all SMA patients and is a
primary target for SMA therapeutic development [13]. In addition
to the identification and development of small molecules that
stimulate full-length SMN2 expression, RNA modalities such as
antisense oligonucleotides (ASO), TOES/bifunctional RNAs and
trans-splicing RNAs have shown promise in SMA cell-based
models [14–20]. ASOs have also been shown to modulate SMN2
expression in vivo in an unaffected transgenic mouse expressing the
human SMN2 gene [18].
In this report, we demonstrate that trans-splicing efficiency is
enhanced by competitively disabling a downstream splice site. As a
means to develop a tractable molecular modality, a series of
antisense RNAs were screened to identify a sequence that would
disable SMN exon 8 and promote trans-splicing. In vitro assays
identified an enhancing antisense RNA and were constructed into
a novel single vector system individually expressing the trans-
splicing RNA and the antisense RNA. Cell-based assays identified
a highly efficient vector system that resulted in high levels of trans-
splicing and correspondingly high SMN protein levels and
increased SMN activity in SMA-derived extracts as measured by
snRNP assembly assays. Intracerebroventricular delivery of the
ASO-tsRNA vector in the SMA mouse model increases SMN
protein in the central nervous system of affected animals,
demonstrating a platform that can significantly elevate SMN
levels in vivo and in a relevant disease context.
Results
Competitive inhibition of downstream splice site
enhances SMN trans-splicing
The key to introducing trans-splicing in vivo and in clinical
settings is by developing efficient trans-splicing systems. We have
previously described a SMN trans-splicing system that significantly
elevated full-length SMN protein levels in SMA patient fibroblasts
[15]. However, initial in vivo experiments failed to achieve similar
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3468levels of activation (data not shown). Therefore, we initially
examined SMN2 trans-splicing with the goal of devising strategies
to enhance trans-splicing efficiency in vivo.
InSMN2trans-splicing,therearethreepotentialsplicingoutcomes:
full length (FL), truncated (D7) and trans-spliced mRNA (TRANS*)
(Figure 1A). Since pre-mRNA splicing is a highly dynamic process,
we hypothesized that competition exists between the trans-splicing
event and the naturally strong SMN2 exon 8 splice site. Thus,
competitive inhibition of the exon 8 splice site would enhance trans-
splicing efficiency. To address this possibility, two complementary
experiments were performed. A previously described slow-polymer-
ase encoding plasmid was co-transfected with the SMN2 mini-gene
and the plasmid expressing the SMN trans-splicing RNA [21]. Under
these experimental conditions, the exon 8 39 splice site approxi-
matelytwokbdownstreamfromexon7,shouldnotbesynthesizedas
quickly as the natural polymerase, therefore, potentially favoring the
trans-splicingevent. Consistentwith the hypothesis, in the presence of
the slow transcribing polymerase, trans-splicing was substantially
increased over the typical level of trans-splicing previously observed
(Figure 1B). Additionally, a SMN2 mini-gene was used in a separate
experiment in which the intervening intron between SMN2 exons 7
and 8 was deleted. In the absence of an intact acceptor site at the
intron 7/exon 8 junction, SMN trans-splicing was again elevated
several fold over the standard SMN2 mini-gene (Figure 1C).
Collectively, these results demonstrate that competitively disabling
t h ed o w n s t r e a ms p l i c es i t ec a nl e a dt oe n h a n c e dtrans-splicing
efficiency, either through a biochemical means or by a genetic
alteration.
Identification of anti-sense RNA that enhances SMN
trans-splicing
The previous experiments provided the impetus to identify a
more tractable molecular mechanism to enhance SMN trans-
splicing, such as antisense molecules. Antisense oligonucleotides
(ASO) have proven to be an effective molecular means to
modulate pre-mRNA splicing, primarily by inhibiting splice site
selection. A panel of plasmids expressing short 18–22 nt ASOs
complementary to the intron 7/exon 8 splice site were constructed
and used to determine whether any of the SMN antisense RNAs
could enhance trans-splicing. (Supplemental Figure S1A, S1B, see
Methods) The ASO-expressing plasmids were co-transfected into
HeLa cells with the SMN2 mini-gene and the pM13 which
expresses the SMN trans-splicing RNA. A single lead candidate was
identified that significantly elevated trans-splicing levels: ASO
pIn7
11. ASO In7
11 overlaps the intron 7/exon 8 boundary
(Figure 2A). Other ASO did not increase trans-splicing from the
SMN2 mini-gene, or in some instances, even inhibited trans-splicing
(Figure 2B, 2C). These results confirm the genetic experiments
that ASO inhibition of a downstream splice site can significantly
enhance trans-splicing efficiency in a mini-gene context.
To determine whether ASO-enhanced trans-splicing occurred in
a more complex context of endogenous SMN gene expression,
pIn7
11 and pM13 was co-transfected into HeLa cells to examine
trans-splicing with endogenous SMN transcripts. HeLa cells express
SMN1 and SMN2 genes and provide a robust level of target RNA.
Consistent with the mini-gene analysis, endogenously derived
trans-spliced SMN increased in a dose dependant manner with
increasing amounts of pIn7
11 (Figure 3A). To examine trans-
splicing in a more disease-specific context, similar co-transfections
were performed in primary SMA patient fibroblasts, 3813 cells.
The cells are derived from a severe Type I SMA patient and lack
endogenous SMN1, and consequently contain very low levels of
SMN-enriched nuclear structures called gems and express very
low levels of full-length SMN protein. Extracts generated from
3813 cells co-transfected with pM13 and increasing concentrations
of ASO pIn7
11 were analyzed for SMN levels using a SMN
monoclonal antibody. Western blots demonstrated an ASO dose-
dependent protein induction greater than control-treated 3813
cells as well as pIn7
11 alone treated cells (Figure 3B). SMN levels in
the co-transfected cells were comparable to SMN levels detected in
the unaffected control fibroblasts, 3814 cells. These results
demonstrate that endogenous SMN transcripts can be re-directed
by trans-splicing and that SMN levels can be significantly increased
by the ASO/trans-splicing strategy in a relevant disease context.
Development of a single vector for anti-sense and trans-
splicing RNA delivery
In envisioning a therapeutic application, a dual vector strategy is
likely to reduce the efficiency of trans-splicing. Therefore, a single
vectorwasconstructedthatwascombinedthemolecularconstituents
of pM13 and pIn7
11 by subcloning the SMN trans-splicing cassette
into the pIn7
11 plasmid backbone. This single vector platform allows
fortheproduction oftwo individualRNAsthattargetdistinctaspects
of SMN pre-mRNA, leading to enhanced full-length SMN
expression (Figure 1A). The ASO-tsRNA plasmid (pMU3) produces
three gene products, the Pol II-derived tsRNA
M13, the Pol III-
derived ASO In7
11, and the Pol II-derived eGFP. Consistent with
the co-transfections, thesinglepMU3vector resulted inhigh levels of
SMN trans-splicing between endogenous HeLa cell SMN transcripts.
SMN levels were elevated nearly three fold compared to the pM13
vector and a pMU3 vector that lacks the promoter that drives the
In7
11 RNA (pMU3
KO) (Figure 4A). The pMU3 vector was also
capable of re-directing endogenous SMN pre-mRNA splicing in
primary SMA fibroblasts, resulting in approximately a three-fold
increaseoverpM13levelsof trans-splicingand a comparable increase
in steady state levels of SMN protein (Figure 4B).
Trans-splicing restores SMN-dependent major and minor
snRNP assembly
To monitor the functionality of the SMN protein produced
downstream of the trans-splicing event, SMN protein function was
measured by in vitro snRNP assembly assays. The best described
activity for SMN is a role in UsnRNP assembly [22]. Using SMN-
deficient extracts from 3813 cells that normally support very low
levels of snRNP assembly, extracts were generated from cells
transfected with salmon sperm DNA, pM13, pIn7
11, or pMU3.
Extracts derived from pMU3 transfected cells exhibited a two to
four-fold increase compared to untreated extracts, demonstrating
that the trans-splicing event not only generates higher levels of
protein, but that SMN protein produced through this pathway is
functional in a critical cellular process ascribed to native SMN
(Figure 5A, 5B). These assays examined the ability of SMN to form
snRNP on a U1 snRNA, which is part of the major spliceosomal
pathway, however, SMN has also recently been shown to be
involved in snRNP biogenesis of the minor spliceosome pathway,
including the U11
ATACsnRNA [23]. To determine if this critical
function was also restored in trans-splicing treated cell extracts,
similar in vitro assembly assays were performed using a
U11
ATACsnRNA (Figure 5C). Consistent with the U1 results,
pMU3 treated extracts were able to significantly elevate functional
SMN levels as measured by U11
ATACsnRNP assembly. Collec-
tively, these results demonstrate that the pMU3 system results in
high levels of functional SMN protein that is capable of
performing UsnRNP biogenesis of the major and minor
spliceosomal pathways to levels comparable to unaffected cells.
A frequently examined biomarker for SMN is a sub-cellular
structure called gems. Gems are nuclear foci enriched in SMN and
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transcripts alternative splice producing two mRNA products. The alternative splicing pathway is represented by gray dashed lines, SMN2 mRNA
products: ‘‘D7’’- Exon 7 skipped, ‘‘FL’’- full length. Trans-splicing RNA identifies SMN2 pre-mRNA intron 6 which overlaps the endogenous branch point
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to monitor the efficiency of SMN induction from a variety of
therapeutic molecules, ranging from drugs to viral vectors. To
determine whether pMU3 increased SMN gems, fibroblasts
transfected with pMU3 plus a panel of negative controls were
examined by indirect immunofluorescence. Transfected cells were
readily detected due to the GFP expression from the plasmid
backbone. In GFP-positive 3813 cells, pMU3 treated gems levels
were significantly increased, resulting in nearly 60 gems per 100
nuclei and with approximately 30–40% of transfected cells
expressing at least one to two gems (Figure 6A, 6B). Negative
controls for fibroblast transfection and cellular reaction included
plasmids lacking a viable tsRNA promoter sequence and empty
pMU2 plasmid demonstrated therapeutically irrelevant increases
in gem numbers (Figure 6A). Therefore we concluded that the
ASO-tsRNA technology achieves the greatest biological impact
relative to previous SMN2 exon 7 trans-splicing theories in these
well-characterized in vitro assays.
pMU3-mediated trans-splicing increases SMN protein in
SMA mice
To determine whether the cell-based analysis of pMU3
translated into comparable results in vivo, SMN proteins were
examined in a previously described mouse model of SMA, referred
to as SMND7 [24]. The SMA murine model expresses the genomic
human SMN2 gene and the human SMND7 cDNA. SMA neonatal
mice were injected into both cerebral lateral ventricles with pMU3
or pM13 at 1.14610
12 plasmid copies using 25 kDa linear PEI
and glucose. Negative control injections contained glucose, saline,
and 25 kDa linear PEI to control for procedure and cytotoxicity.
After 24 hours the spinal cord was dissected and used to generate
total RNA and protein extracts. Utilizing trans-splicing specific
RT-PCR primers we identified a positive trans-SMN mRNA
product in the spinal cord (Figure 7A). Northern and southern
blotting using a GFP-specific probe demonstrated that similar
levels of plasmid were present in each of the treated SMA mice
(lower panel Figure 7A, and data not shown, respectively).
Western blots of disassociated whole spinal cord extracts from
five individual pMU3-treated SMA pups were examined and
shown to contain significantly elevated levels of SMN protein.
pMU3-induced levels of SMN were significantly higher than
untreated SMA mice and were comparable to SMN levels
detected in homogenates from unaffected heterozygotes
(Figure 7B). In contrast, the parental vector that lacked the
ASO, pM13, did not result in significant levels of SMN induction
(Figure 7C, 7D). Similarly, the ASO-alone vector failed to induce
SMN levels in vivo (data not shown). Taken together, these results
demonstrate that the pMU3 vector strategy that encodes two
separate RNAs significantly increases SMN trans-splicing and
provides the first demonstration of SMN trans-splicing in vivo.
Discussion
This is the first demonstration of a technique designed to
enhance trans-splicing efficiency by blocking downstream splice site
selection. While the initial trans-splicing RNA alone showed
considerable activity in cell-based models of SMA in terms of
significantly increasing SMN levels and increasing snRNP activity
[15], these results did not translate to the in vivo context. Our
research highlights a key finding that low dose trans-splicing is
enhanced by the co-expression of the ASO and resulted in
detectable levels of SMN expression in vivo.
As a therapeutic approach, trans-splicing offers the advantage
over gene replacement in that expression is intrinsically controlled
by the endogenous promoter [7]. Consequently, temporal and
spatial constraints on gene expression are retained. As SMN
expression has previously been shown to be significantly down-
regulated from embryogenesis to adulthood, this additional
restraint may prove beneficial for long-term exposure to a SMN
trans-splicing vector. Avenues of research directed to the reduction
of tsRNA vector dosage would consequently inhibit the negative
effects of off-target trans-splicing over greater amounts of time.
The genetic context of SMA represents an intriguing target for a
number of therapeutic strategies, including trans-splicing. In the
SMN2 gene, the intrinsic quality of the exon 7 splice acceptor site is
reduced due to the C/T transition. Therefore, the competition
between SMN2 cis-splicing and trans-splicing is likely reduced,
providing a potential advantage to trans-splicing in the SMN context
compared to other alternatively regulated exons that retain fully
functional splice sites. We propose trans-splicing is further enhanced
relative to cis-splicing with the introduction of an inhibitory ASO.
Since the tsRNA annealing domain hybridizes over the target exon,
it is logical that this may promote exon 7 skipping. Therefore, the
addition of the anti-sense likely blocks this escape pathway and
further promotes trans-splicing. Unlike many ASOs that modify
splicing, the ASOs used in this context are native RNA structures,
not oligonucleotides with modified backbones. Therefore, the affects
may be difficult to observe at steady-state levels when used as an
ASO alone. However, given that this sequence overlaps the intron
7/exon 8 boundary, itwas not surprising that the ASO recapitulated
the increase in trans-splicing observed with the slow polymerase and
intron 7-deleted construct.
In general, the field of trans-splicing therapeutics can benefit
from the discovery of combined ASO-tiling and tsRNAs. ASO-
tiling increases the potential of tsRNA by modulating cis-splicing
signals within the target transcript. Additionally, in a novel
application of ASO-In4
11 and tsRNA
EX4 co-delivery targeting a
upstream SMN intron 3 exon 4 splicing context produced
enhancement of basal trans-splicing. (Supplemental Figure S2)
Studies here demonstrate the limitations of dual vector delivery in
difficult fibroblast transfection conditions. Co-transfection dynam-
ics hinder the potential of ASO/tsRNA pre-mRNA redirection
then incorporated in the final mRNA is catalyzed by the spliceosome. Circles surrounding symbol ‘‘BP’’ identifies known branchpoints in the model.
We demonstrate a novel mechanism of disrupting downstream intron 7 splicing elements causes enhancement of trans-splicing. (Bold ‘‘TRANS*’’ and
large black arrow indicate enhanced trans-splicing pathway). The effect is accomplished via enhancing Antisense Oligonucleotides ‘‘ASO In7
11’’
targeted to the distal intron and exon boundary. The stop codons ‘‘STOP’’ and SMN2 ‘‘C-T’’ or tsRNA ‘‘C*’’ nucleotide changes are denoted with
vertical line marking approximate RNA position. Bracketed objects indicate promoters and gene products produced from pMU3 plasmid pictured
below by a black line. (B) Increasing concentrations of transcription mutant RNA polymerase promotes trans-splicing. HeLa cells were transfected of
static amounts mini-gene pSMN1 (lane a) or pSMN2 (lanes b–g) 1.25 mg , pM13 (lanes c–g) 0.75 mg, and increasing amounts of mutant Rpb1 RNA
Polymerase subunit (pAT7-Rpb1MT) at 0.25, 0.75, 1.0 and 2.0 mg were harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH
normalization control. (C) A genetically disabled SMN2 intron 7 deletion mini-gene displays enhances trans-splicing at reduced tsRNA plasmid
concentrations. HeLa cells were cotransfected with pSMN1 (lane a), pSMN2 (lanes b,d), pSMN2
DIn7 (lanes e–h) 1.25 mg each and increasing
concentrations of pM13 (lane d) 0.25 mg, (lanes e–h) 0.10, 0.25, 1.0 and 2.0 mg and the RNA harvested at 48 hrs. Reverse transcriptase PCR gel is
displayed with GAPDH normalization control.
doi:10.1371/journal.pone.0003468.g001
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pMU3. The combination of ASO-tsRNA mechanism and a novel
single vector platform produces a potent enhancement of basal
trans-splicing. In the case of trans-splicing RNAs designs such as, 59
or 39 versions would require examination of beneficial upstream
and downstream sequences to tile with ASO RNA.
The in vivo results demonstrate ASO-tsRNA represents a
tractable therapeutic yet highlight the transient nature of plasmid
transfections. The use of AAV vectors for the delivery of gene
therapies would provide a substantial longevity to ASO-tsRNA
expression and thus SMN2 redirection. Future studies could
examine the role of expression of the virus vectors and the SMA
CNS. We conclude the combined effects of ASO-tsRNAs in a
novel expression vector enhanced trans-splicing in the context of
SMN2 alternative cis-splicing. Applications of this biotechnology
on a well characterized SMA model mouse demonstrate the
promise of in vivo restoration of SMN via trans-splicing RNAs.
Materials and Methods
Plasmids and cloning
The pMU2-tsRNA
M13 clone reported previously is now written as
pM13 [15]. The SMN1 and SMN2 mini-genes (pSMN1,p SMN2)h a v e
been previously described [12]. Mini-gene pSMN2
DIn7 was created
by using overlapping PCR primers which anneal the 59 splice donor
of exon 7 to the 39 splice acceptor of exon 8. SMN In7 DEL FWD
(59- TCCTTAAATTAAGGAGAAATGCTGGCATAGAGC-39)
This PCR product was then gel purified and cloned into the pCI
minigene using 59-NheI and NotI-39.T h ep l a s m i dp A T 7 - Rpb1-
(N792D) (R749H) expresses the mutant RNA polymerase [21]. The
Antisense Oligonucleotides (ASO) was cloned into the previously
reported pMU2 plasmid context driven by a U6 promoter [14].
Sequences were chosen with intron 6 dentoted as In6
X (with X
indicated the sequential number) and intron 7 as In7
X.L i s t e db e l o w
are the binding domains for the ASO as read 59 to 39 in the SMN pre-
mRNA [SMN EXON 6]59-( I n 6
1-59-uucugaucauauuuuguu-
gaauaaa-39)( I n 6
2-59uuuguugaauaaaauaaguaaaaug) (In6
3-59auaa-
guaaaaugucuugugaaacaaa) (In6
4-59gucuugugaaacaaaaugcuuuuuaa)
(In6
5-59aaugcuuuuuaacauccauauaaag) -39[SMN EXON7]59-
(In7
1-59auaugggaauaaccuaggcauacugca) (In7
2-59cuaggcauacugcacu-
guacacucug) (In7
3-59cacuguacacucugacauaugaagug) (In7
4-59acauau-
gaagugcucuagucaa) (In7
5-59gcucuagucaaguuuaacuggugucca) (In7
6-
59uuuaacugguguccacagaggacau) (In7
7-59acagaggacaugguuuaacugga)
(In7
8-59gguuuaacuggaauucgucaagcc) (In7
9-59ggaauucgucaagccucug-
guucuaauuu) (In7
10-59ugguucuaauuucucauuugcagG) (In7
11-59ucu-
cauuugcagGAAAUGCUGGCAUA) -39[SMN EXON8] (In
712-
59AAUGCUGGCAUAGAGCAGCACUAAA) (In7
13-59AUGA-
CACCACUAAAGAAACGAUCA) (In7
14-59AAGAAACGAUCA-
GACAGAUCUGGAA) The pMU3 construct produces three gene
products, tsRNA, eGFP protein and ASOs. ASO-In7
11 was
subcloned by PCR Platinum Pfx DNA Polymerase (Invitrogen)
amplification according to the manufacture instructions of the U6
promoter and the antisense RNA and cloned by flanking restriction
sites 59-BlpI and AsiSI-39(NEB). pMU3
KO is a substitution of the
In7
11 anti-sense RNA with a random sequence of RNA created by
overlapping PCR and cloned using the same restrictions sites above.
The pMU2-tsRNA
EX4 intron 3 binding domain was amplified from
HeLa genomic DNA using primers (Int3 Rev 59- ATCAAGCTT-
GAGCTCAAAAAGAAAAAATATGCAGGTTTT-39) and (Int3
Figure 2. ASO mediated inhibition of downstream splicing
increases SMN2 trans-splicing. (A) HeLa cells transfected with static
amounts of pSMN1 (lane a), pSMN2 1.25 mg (lanes b–e) and pM13 (lane
c–e) 0.75 mg are cotransfected with increasing concentrations of pIn7
11
(lane d,e) 0.25, 1.0 mg and RNA harvested at 48 hrs. Reverse
transcriptase PCR gel is displayed with GAPDH normalization control.
Graph represents independent triplicate repeats using a quantitative
M13-Cy3 labeled primer and linear-range PCR amplification. Inset graph
represents the average of triplicate repeats and error bars indicate 6s.d.
(B) SMN intron 6 ASO controls contribute to a reduction of trans-
splicing. HeLa cells were triple transfected with static amounts of mini-
gene pSMN1 (lane a) pSMN2 (lane b–g) 1.25 mg and pM13 (lane c–g)
0.75 mg with increasing amounts of pIn6
5 (lane e–g) 0.25, 0.75 and
1.0 mg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is
displayed with GAPDH normalization control. pIn7
11 (lane c) 1.0 mg
serves as a positive ASO-tsRNA control. (C) ASOs targeted internally to
SMN intron 7 reduce trans-splicing. HeLa cells were triple transfected
with static amounts of mini-gene pSMN1 (lane a) pSMN2 (lanes b–g)
1.25 mg and pM13 (lanes c–g) 1.0 mg with increasing amounts of pIn7
1
(lanes e–g) 0.25, 0.75 and 1.0 mg and RNA harvested at 48 hrs. Reverse
transcriptase PCR gel is displayed with GAPDH normalization control.
pIn7
11 (lane c) at 0.25 mg serves as a positive ASO-tsRNA control.
doi:10.1371/journal.pone.0003468.g002
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39) and cloned into HindIII-SacII of pcDNA3/PTM2 replacing Int6
binding domain. Exons 4–7 were amplified from SMN1 cDNA clone
using primers (Ex4 Fw 59-TCAGATATCCTGCAGAGAAT-
GAAAATGAAAGCCAAGTTT-39)a n d( E x 7R e v5 9- CATTCTC-
GAGGGGCCCGTCATAGCTGTTTCCTGCGACTCCTTAA-
TTTAAGGAATGTGAGCA-39) and cloned into EcoRV and XhoI
sites of pMU2. The In4
11 antisense fragment was amplified from
pMU3 construct using BsrGI In7
11 (Fwd 59-AGCTGTACAAG-
TAAAGCGGCCGCGACTCTAGATC-39)a n dM l u II n 4
11 (Rev
59- GTAACGCGTAAAAAATTCCTTATAGCCAGGTCTAAA-
ATGGATCCGAAGACCACAAACAAG-39) and was cloned to
make pMU2-In4
11, the antisense fragment into the BsrGI-MluI sites
of pMU2 vector. Ligations were carried out using 10–15 units of T4
DNA Ligase (NEB) at 15uC for 24 hours and transformed in
Subcloning Max Efficency DH5a. (Invitrogen) Sequencing of gel
purified trans-splicing SMN M13 positive cDNAs produced from in
vivo murine RT-PCR was performed using 1.5 ng of hSMN Exon 6
Forward primer and on a ABI 3730 DNA Analyzer and Applied
Biosystems Big Dye Terminator system and read by Chromat
Freeware.
In vitro Transfections
The transfections were performed using linear PEI (Poly-
sciences, Inc.) to pH 8.3 with 20 mL adjustments of HCl or
NaOH. Stock linear 250 kDa PEI for HeLa in vitro transfections
were snap frozen in liquid nitrogen and thawed 5 times at 37uC.
Triple transfections in HeLas required ‘‘mean-low molecular
weight PEI,’’ stock PEI was sonicated on ice at 30% total power
for 30 seconds three times. Plasmids were transfected into HeLa or
HEK293 cells (Coriell Cell Repositories) grown to 80% confluence
before transfection. Plasmids were diluted in a 150 mM NaCl
solution before adding filtered linear 7.5 mM 250 kDa PEI. Cells
were incubated with plasmid overnight and replenished with fresh
Dulbecco’s Modified Eagle Media High Glucose 16DMEM
+ (D-
glucose 4.5 g/L, +L-glutamine, 1% penicillin/streptomycin
10 000 units/mL, 3% fetal bovine serum-endotoxin free) and
harvested 48 hours post-transfection. Controls include salmon
sperm DNA (ssDNA) (Invitrogen) and normalized across co-
transfection samples to greatest treatment plasmid DNA micro-
grams. SMA patient fibroblasts (GM3813) were transfected with
Lipofectamine
TM2000 with LiCl (5M) centrifuge purified plasmid
in serum free DMEM
2 for 4 hours then washed via media and
replaced with DMEM
+ for 2 hours. Finally complete media
DMEM
+ was added back for the remaining incubation. Cells were
harvested 24 hours later in PBS (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 2 mM KH2PO4) pH 7.5–8.0. ASO-tsRNA
co-transfections used ssDNA to control for total volume of DNA.
Post-transfection harvested cells were counted on a hemocytom-
eter and use Trypan blue dye exclusion to determine viable cell
counts per microliter.
RT-PCR
48 hours post transfection or transduction, total RNA was
harvested from cells using TRIzol Reagent (Invitrogen) according
to the manufacturer’s instruction. Total RNA concentration
determined via Nano-drop OD260 and normalized before cDNA
synthesis. RT-PCR was performed as previously described [14].The
trans-splicing product was amplified using a reverse primer M13 (59-
GTCATAGCTGTTTCCTGCGAC-39)5 9 Cy3 labeled (564 nm
emission max) (Intergrated DNA Technologies, Inc.) and a mini-
gene specific primer, pCI-Fwd [12]. The SMN1 and 2 mini-gene
transcriptswereamplifiedusingpCI-Fwd#1andpCI-Rev[12].The
primers used in endogenous PCR amplifications were an SMN Exon
6 -Forward (59-CCCCCACCACCTCCCATATGT-39)a n dSMN
Exon 8-Reverse (59-AGTGGTGTCATTTAGTGCTGC-39). The
endogenous pMU2-tsRNA
EX4 mediated trans-SMN product was
amplified using primer Exon 3
+126 (Fwd 59-GAGAGGAGCAAA-
ATCTGTCCGATCTAC-39) and M13 Rev. The endogenous trans-
spliced product is amplified by SMN Exon 6 (+7) Forward and M13
Reverse. Negative RT polymerase controls were included in
protocol but omitted from final figures. Semi-quantitative determi-
nations via Cy3 labeled trans-splicing products were imaged using
laser Fuji-Imager FLA5000 at 550 nm excitation range. RT-PCRs
were repeated in triplicate to confirm 2-tail t-test statistical
significance of the increase in trans-SMN mRNA. To normalize
within experiments, trans-SMN induction is determined as (trans-
SMN:GAPDH) and between experiments levels were normalized to
basal pM13 trans-splicing values (set to 1). SMN trans-splicing was
measured using fold change over pM13 set to 1 as expressions of
trans-splicing efficiency.
Figure 3. Endogenous enhancement of trans-splicing utilizing combined delivery of ASO and tsRNA. (A) Dose dependant ASO In7
11
enhancement of endogenous SMN trans-splicing. HeLas were cotransfected with pM13 (lanes a–e) 1.0 mg and increasing concentrations of ASO
pIn7
11 (lanes c–e) 0.25, 2.0 and 5.0 mg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control.
pIn6
5 (lane a) 2.0 mg serves as a negative control. (B) Dose dependant ASO pIn7
11 enhancement of pM13 mediated SMN protein induction. 3813 SMA
patient fibroblasts were co-transfected with pM13 (lanes d–f) 0.75 mg and increasing concentrations of pIn7
11 (lanes d–f) 0.50, 1.0 and 2.0 mg and
cells harvested at 24 hrs and run on 10% SDS-PAGE. pIn7
11 alone (lane c) 2.75 mg and ssDNA (lanes a, b) 2.75 mg serve as negative controls. b-actin
antibody panel serves as a normalization control.
doi:10.1371/journal.pone.0003468.g003
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SMA patient fibroblasts (Coriell Cell Repositories, 3813 cells)
harvested at sub-confluent levels were plated for transfections on
UV irradiated glass coverslips. Prior to harvest, samples were
washed twice in PBS pH 7.5. Fixation of cells was performed using
cold acetone/methanol (50:50) [14]. 1% BSA was used as a
blocking medium for 1 hour then the samples were washed in PBS
pH 7.0. Primary antibody 4B7 mouse anti-SMN was diluted 1:500
in PBS. Secondary antibody (goat anti-mouse Texas Red-594:
Jackson Immuno-Research Laboratories) were used according to
manufacturer’s instructions. Cells were washed with PBS and
nuclei stained with DAPI [25]. Microscope images were captured
on Nikon Eclipse E1000 using Meta-Morph software. Control
exposures determining levels of background for the secondary in
the absence of primary antibody set basal limits for SMN
detection. These controls are performed during each experimental
round to control for intra-assay perturbations.
Western blot
HeLa cell pellets were prepared in RSB100 lysis buffer (20 mM
Tris-HCl pH 7.4 100 mM NaCl, 25 mM MgCl2, Triton 6100
0.5%) and centrifuged at 10,000 g for 5 min at 4uC. Samples were
sonicated and boiled in loading dye then resolved in a 10% SDS-
PAGE 20 cm610 cm BioRad Protean xi Glass plates using
Protean 2000. Resolved proteins were then transferred to PVDF
(Immoblion) at 200 mAmps for 400 minutes in Towbins (24 mM
Tris base, 192 mM glycine, 20% methanol (v/v)). Western blots
were blocked overnight in 5% Casein and Tris-buffered Saline
(TBS
T) (90 mM Tris-HCl, 10 mM KCl, 547 mM NaCl, 2%
Tween (v/v) (Acros)) pH 7.5. Primary patient fibroblast western
blots were probed with 1:100 dilution of mouse anti-SMN
monoclonal antibody, 4B7 [25], and visualized with a HRP-
conjugated secondary mouse antibody. Murine western blots were
probed with 1:1000 dilution of mouse anti-SMN (BD Biosciences)
and were produced using 1:1 mixture of Peirce West Pico reagent.
Cross reaction with endogenous mouse heavy and light chain
antibody Mouse TrueBlot
TM ULTRA HRP anti-mouse IgG
(eBioscience) was used at 1:10 000 in 5% skim milk. Images were
captured and quantitated using a Fuji Imager LAS 3000 at 75% of
total resolution 10–30 second exposure and Multi-Gauge V2.3
system. To control for loading error the westerns were then
stripped using H2O2 for 15–20 minutes at room temperature and
re-probed with anti-b-actin rabbit and anti-rabbit HRP. Western
blots were repeated in quadruplicate to confirm 2-tail t-test
statistical significance of the increase in SMN protein. To
normalize within experiments, SMN induction is determined as
(SMN:b-actin) and between experiments SMN levels is normalized
to GM3813 values (triplicate mean set to 1). SMN protein
induction was measured using pIn7
11 ASO as baseline, and fold
change over pM13 alone (triplicate mean set to 1) as expressions of
trans-splicing efficiency.
In vitro snRNP assembly reactions
Cloned U1 snRNA (DSm) cDNA has the Smith core site (59-
AUUUGUGG-39) sequence deleted to inhibit non-specific
products [26]. The U1 snRNA (WT and DSm) was in vitro
transcribed using the Maxi-prep (Invitrogen) plasmid pT7 cleaved
with EcoRI for 3 hours and cleaned up with PCR columns
(Invitrogen). U11
ATAC snRNA was synthesized with mature post-
transcriptional modification sequences and cloned into pGA4
(GENEART) flanked by T7 sequences. Transcriptionally compe-
tent snRNA
ATAC templates were created with primers and high
fidelity PCR amplification (Roche). U11FWD #1( 5 9-GATC-
GATCTAATACGACTCACTATAGGGAGAATTCAAAAAG-
Figure 4. Development of a single plasmid ASO-tsRNA system
(pMU3) enhances endogenous SMN trans-splicing. (A) pMU3
enhances trans-splicing capabilities in a single vector. HeLas were
transfected with pM13 (lane a) 0.75 mg or pMU3
KO (lane b) 0.75 mgo r
pMU3 (lanes c,d) 0.75 and 1.0 mg and RNA harvested 48 hrs later.
Reverse transcriptase PCR gel is displayed with GAPDH normalization
control. Inset graph represents triplicate repeats. (B) In SMA relevant
contexts the single plasmid ASO-tsRNA system (pMU3) produces the
greatest amount of trans-splicing. 3813 SMA patient fibroblasts were
transfected with pM13 for basal level (lane c) 0.75 mg or cotransfected
with pIn7
11 0.50 mg and pM13 0.50 mg together (lane d) or pMU3 (lane
e) 0.75 mg and RNA harvested at 48 hrs. ssDNA (lane a) 0.75 mg and
pIn7
11 alone (lane b) 2.0 mg serve as negative controls. Reverse
transcriptase PCR gel is displayed with GAPDH normalization control.
Inset graph represents the average of triplicate repeats and error bars
indicate 6s.d.
doi:10.1371/journal.pone.0003468.g004
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produces functional SMN protein in patient fibroblasts. (A) The
pMU3 single plasmid ASO-tsRNA system produces the greatest amount
SMN protein induction. 3813 SMA patient fibroblasts were transfected
with pM13 for basal level (lane d) 0.75 mg or cotransfected with pIn7
11
0.50 mg and pM13 0.50 mg together (lane e) or pMU3 (lane f) 0.75 mg
cells were harvested at 24 hrs and run on 10% SDS-PAGE. ssDNA (lanes
a,b) 0.75 mg and pIn7
11 alone (lane c) 2.0 mg serve as negative controls.
b-actin antibody panel serves as a normalization control. Inset graph
represents the average of triplicate repeats and error bars indicate 6s.d.
(B) The pMU3 system restores SMA primary fibroblasts in vitro capacity
to assemble U1snRNP. 3813 SMA patient fibroblasts were transfected
with pM13 (lane e) 0.75 mg for basal level or pMU3 (lane d) 0.75 mg cells
were harvested at 24 hrs and S100 extract prepared. ssDNA (lane b)
0.75 mg and pIn7
11 alone (lane c) 2.0 mg serve as negative controls.
Inset graph represents the average of triplicate repeats and error bars
indicate 6s.d. (C) The pMU3 system restores the SMA primary
fibroblasts in vitro capacity for minor spliceosome U11 snRNP assembly.
3813 SMA patient fibroblasts were transfected with pMU3 (lane d)
0.75 mg or ssDNA (lanes b,c) 0.75 mg. ssDNA. 3813 and 3814 (lanes b
and c) serve as negative and positive controls respectively for U1 and
U11
ATAC assembly. (*) indicates band of interest.
doi:10.1371/journal.pone.0003468.g005
Figure 6. pMU3 transfected SMA primary fibroblasts display
increased gem numbers. (A) 3813 SMA patient fibroblasts were
transfected with pMU3 0.75 mg or ssDNA 0.75 mg and fixed at 24 hrs.
Immunohistochemistry was performed using aSMN antibody 4B7 and
visualized with Texas Red 594, nuclei with DAPI. White arrows indicate
examples of gem structures in the red anti-SMN panel. (B) Graphical
summary of averaged SMN gem counts in 300 GFP positive 3813
fibroblasts. Error bars represent 6SD. Statistical significance relating
pM13 to pMU3 determined by values of p,0.05.
doi:10.1371/journal.pone.0003468.g006
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TCTAAATCCACTGTGATATCTTCTCAAAGGGCGCCGG-
GACCAA-39) The T7-U11
ATAC PCR product was PCR purified
and used in subsequent transcription reactions as a template.
snRNA transcription reactions: 10 units of T7 RNA polymerase
HC (Ambion), ARCA-Methyl cap (Ambion) and rNTPs supple-
mented with P
32 labeled rUTP was incubated for 30 minutes at
30uC. Cells were harvested and lysed in on ice via fresh
Reconstitution Buffer (20 mM Hepes-KOH pH 7.9, 50 mM
KCl, 5 mM MgCl2, 0.2 mM EDTA, 0.01% Triton 6100).
Cytoplasmic and nuclear fractioning was accomplished by
centrifugation at 1000 rpm for 15 minutes at 4uC. The S100
fraction was removed and (76) EDTA free protease inhibitor
cocktail (Roche) added to preserve the SMN complex. Assembly of
the Sm cores occurred for 30 minutes at 30uC using 20U of
RNAsin (Promega) added to 50 mg total of S100 extract at final
concentration of 2.5 mM ATP, 1.0 mg Yeast tRNA, U1 snRNA
(100,000 cpm). For the general assembly in the U11
ATACsnRNA
75 mg total extract was required for 60 minutes at 30uC. Following
assembly, 350 uL of DEPC-RSB
200 buffer was used in the initial
immunoprecipation (IP) steps via primary bead fractions Protein G
Plus/Protein A Agarose suspension with PBS (Oncogene) pre-
blocked with 25 mg of whole HeLa cell extracts. Bead fractions are
pre-incubated with 1 uL anti-Mouse Y12 mono-clonal antibody
(Lab Vision) per 50 mL stock slurry volume. Radio-IPs were
processed at 4uC to reduce signal loss and washed at 25uC.
UsnRNP and beads were denatured in (56) formamide loading
dye and run on an 8% acrylamide TBE-Urea gel (45 mM Tris-
borate, 1 mM EDTA, 7M Urea). Quantitative measurements of
snRNP products were derived after a 30–45 minutes exposure on
a phospho-screen (Kodak). Bands were imaged using Fuji-Imager
FLA5000 and Image Reader FLA5000 V2.0 software (IP
2S mode)
normalized to background. The Fuji-imager results were corre-
lated to excised bands via scintillation counter output averaged
over three rounds of counts per minute. Within experiments the
capacity to assemble snRNPs is determined by the ratio of
U1
WT:U1
KO. Between experiments, comparisons were deter-
mined by normalization to GM3813 values (set to 1) and above the
assembly baseline of ASO pIn7
11 transfections. GM3813/3814
fibroblasts were included in the experiment up to the fourth
passage post cryo-preservation rescue to avoid artificial selection of
SMN positive populations.
Intracerebroventricular injection of SMA mice
SMA mouse were genotyped PND 0 via tail clip. Frozen tails were
prepared using a binary HOTShot method: 90uC for 10 minutes
alkalinelysissolution(25 mMNaOH0.2 mMdisodiumEDTA)and
Trizma base neutralizing solution (40 mM Tris-HCl). 1.5–2.0 mL
Figure 7. Intracerebroventricular 25 kDa PEI pMU3 transfec-
tions in SMA model mice increases SMN protein in the spinal
cord. (A) Heterozygous (mSMN +/+,h SMN +/+,h D7 SMN cDNA +/+)
(lane a) or homozygous (lanes b–g) (mSMN 2/2,h SMN +/+,h D7 SMN
cDNA +/+) neonatal mice (PND 0-1) were injected with pMU3 plasmid at
10 mg (1.14610
12 plasmid copies) with 25 kDa PEI over two ventricles
(lanes c–g). Mock transfection mice are shown in lane a and b. Whole
spinal cord homogenates were prepared for protein or RNA extraction
24 hours post injection. In vivo RT-PCR results for trans-spliced SMN are
shown in the upper panel. Lower panel depicts controls for vector
expression via northern blot of mock or treatment group spinal cord
RNA loaded on nitrocellouse and developed with a radio-labeled GFP
probe. (B) SMA mouse spinal cord protein was resolved on 10% SDS-
PAGE. b-actin antibody panel serves as a normalization control. (C)
Intra-ventricular transfections of pM13 in SMA model mice do not alter
SMN levels in the spinal cord. Homozygous (mSMN 2/2,h SMN +/+,
hD7 SMN cDNA +/+) (lanes b,c) neonatal mice (PND 0-1) were injected
with 10 mg of plasmid with 25 kDa PEI over both ventricles. Whole
spinal cord homogenates were prepared for protein and resolved on
10% SDS-PAGE. b-actin antibody panel serves as a normalization
control. Mock treatment is depicted in lane a. (D) Graphical summary of
injection outcomes relative to SMN protein induction western blot in
mice. Error bars represent 6s.d. HET, KO, pM13 (n=4). pMU3 (n=5).
doi:10.1371/journal.pone.0003468.g007
Trans-Splicing In Vivo
PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3468input tail solution was added to PCR reactions containing previously
described, yet renamed for clarity, primer sets mSMN FWD (59-
GCAGCTGTGCTCGACGTTGTC-39), mSMN REV (59-TAA-
GAAAGCCTCAATGTGCTCAAG), hSMN2 FWD (59-GCGA-
TAGAGTGAGACTCCATCT-39), hSMN2 REV (59-GACATA-
GAGGTCTGATCTTTAGCT-39) [27]. PND 2 neonates were
immobilized via cryo-anesthesia and injected using mL calibrated
sterilized glass micropipette 0.25 mm lateral to the sagittal suture
and 0.50–0.75 mm rostral to the neonatal coronary suture. The
needles were inserted perpendicular to the skull surface using a fiber-
optic light (Boyce Scientific Inc.) to illuminate pertinent anatomical
structures. Needles were removed after 15 seconds of discontinua-
tion ofplungermovementto preventbackflow. Micerecovered in5–
10 minutes in a warmed container until movement and general
response was restored. Injection stock solutions contained and final
volumes include: D-(+)-glucose 20% (w/v) (1 mL) (Sigma), trypan
blue (0.4%) saline (1 mL) (Sigma), plasmid (<5 mg/mL) (2 mL),
25 kDa linear PEI homopolymer (150 mM) (1 mL) (Polysciences,
Inc.). In vivo plasmids prepared with endo-toxin free Maxi-prep
(QIAgen) were analyzed for purity and superhelicity in 4% agarose
gels and NanoDrop quantifications. Control mock in vivo
transfections contain glucose, trypan blue saline, 25 kDa PEI and
do not contain plasmid. In vivo western and northern blot was
performed by dissecting the CNS with microsurgical technique via
Roboz RS-5600 (Roboz Surgical Instrument Co., Inc.) and gross
disassociation performed by passing tissue re-suspended in PBS
through a 18-gauge needle and aliquot into individual tubes, then
snap-frozen in liquid nitrogen. Total spinal cord RNA was collected
by TRIzol (Invitrogen) and the final pellet resuspended in 30 mLo f
PrepSolution (40 mM PIPES pH 6.8, 1 mM EDTA, 250 mM
NaCl, 80% (v/v) deionized formamide). The RNA was blotted by
vacuum with BioDot SF (BioRad) seeding on 9612 cm Zeta probe
membranes (BioRad). GFP probes were created by Klenow
fragment synthesis with Easytides dATP creating 10
8 cpm/mg
product used at a final concentration of 10
6 cpm/mL in the
hybridization buffer (500 mM Na2PO4 pH 7.2, 1% SDS, 1 mM
EDTA). In vivo murine trans-splicing RT-PCR was performed with
the previously reported ‘‘human-specific’’ Exon 4 35–55 forward
(Hua et al. 2008) combined with the standard M13 reverse primer.
Statistical analysis
Student t-tests were utilized to gauge significance between two
results via 2-tailed regression analysis. Levels of significance were
set to p#0.05 for a single treatment regiment and repeated in
triplicate to determine mean and 6standard deviation values.
Statistical values are represented as the inset graphs and error bars
indicate 6s.d. for the averages. The data collected was normalized
internally to 1 using a base line controls indicated in the above
method sections. This approach is justified by the number of mice
compared, involved in treatment versus mock, and relative fold
change in the overall protein expression post-treatments using
SMN
KO mouse mock as basal.
Supporting Information
Figure S1 Summary of SMN2 trans-splicing and intron 7 ASO-
tiling screen demonstrates specificity of ASO-In711 effect. (A)
Graphical depiction of intron 7 ASO targets. ASO sequences are
identified at the beginning of the individual string, written 59-39.
Capitalized sequence indicates exon 8 sequences with the 39 splice
site defined in red. The bars located directly below illustrate the
effects on the trans-splicing product by the respective colors. Black
lines indicate neutral effects, red lines indicate negative influences,
and green lines represent increased trans-splicing. (B) Summary of
even numbered intron 7 ASO screen demonstrates no effect.
HeLa cells were triple-transfected with plasmids expressing pM13
1.0 mg, a minigene SMN2 (lanes a–h) 1.25 mg and ASO pIn72-
pIn712 (lanes c–h) 1.0 mg and RNA harvested at 48 hrs. Reverse
transcriptase PCR gel is displayed with GAPDH normalization
control. pIn71 negative control serves to normalized between ASO
experiments. (C) Summary of odd numbered intron 7 ASO screen
identifies pIn711 ASO as a potent enhancer of trans-splicing.
HeLa cells were triple-transfected with plasmids expressing pM13
1.0 mg, a minigene pSMN2 (lanes a–d) 1.25 mg and ASO pIn71-5,
pIn77-11 (lanes b–d) 1.0 mg for blots respectively and RNA
harvested at 48 hrs. Reverse transcriptase PCR gel is displayed
with GAPDH normalization control. pM13 controls for basal
trans-splicing. (D) HeLa cells were triple-transfected with plasmids
expressing a minigene SMN2 (lanes a–d) 1.25 mg, pM13 (lanes b–
e) 1.0 mg, a negative control scrambled ASO-tsRNA vector
pMU3KO (lane a) 1.0 mg and ASO-tsRNA DNA recombination
control transfection with pM13 and pIn711 (lane e) 1.0 mg minus
pSMN2. RNA harvested at 48 hrs. Reverse transcriptase PCR gel
is displayed with GAPDH normalization control. pM13 controls
for basal trans-splicing (lane c).
Found at: doi:10.1371/journal.pone.0003468.s001 (2.16 MB TIF)
Figure S2 The ASO-tsRNA mechanism can be applied to
heterologous contexts. SMA patient fibroblasts co-transfected with
a trans-splicing RNA that targets SMN intron 3 containing SMN
exons 4–7 written as ‘‘pMU2-tsRNAEX4’’ (lanes b–f) (0.25 mg)
with increasing concentrations of enhancing ASO directed toward
the intron 4/exon 5 splice site ‘‘pMU2-In411’’ (c–f) (0.25 mg,
0.50 mg, 0.75 mg, 1.0 mg) produced increased trans-splicing.
Reverse transcriptase PCR gel is displayed with GAPDH
normalization control. Lane a represents negative control omitting
RT polymerase, lane b is base line trans-splicing for pMU2-
tsRNAEX4.
Found at: doi:10.1371/journal.pone.0003468.s002 (1.65 MB
DOC)
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